Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1996-07-18
2000-09-12
Criares, Theodore J.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514380, A61K 3142
Patent
active
061178950
ABSTRACT:
Compounds of formula I ##STR1## are useful for treating TNF-mediated diseases.
REFERENCES:
patent: 4012495 (1977-03-01), Schmiechen et al.
patent: 4153713 (1979-05-01), Huth et al.
patent: 4186129 (1980-01-01), Huth et al.
patent: 4208406 (1980-06-01), Lapinet et al.
patent: 4824838 (1989-04-01), Wachtel et al.
patent: 5227369 (1993-07-01), Rosen et al.
patent: 5420154 (1995-05-01), Christensen, IV et al.
patent: 5541219 (1996-07-01), Fenton et al.
patent: 5672622 (1997-09-01), Hedgepeth et al.
patent: 5783591 (1998-07-01), Klose et al.
Strieter et al., Biochem. Biophys. Res. Comm., 155:1230-1236 (1988).
Taffet et al., Cell. Immunol., 120:291-300 (1989).
Spengler et al., Infec. Immun., 57:2837-2841 (1989).
Reeves et al., Biochem. J., 241:535-541 (1987).
Tracey et al., Nature, 330:662-664 (1987).
Old, Nature, 330:602-603 (1987).
Millar et al., Lancet, pp. 712-713 (1989).
Dezube et al., Lancet, pp. 662-663 (1990).
Perchellet et al., Cancer Letters, 29:127-137 (1985).
Perchellet et al., Carcinogenesis, 3(10):1149-1158 (1982).
Tonelli et al., Endocrinology, 77:625-634 (Oct. 1965).
Seely et al., Proceedings of the Society for Experimental Biology and Medicine, 159:223-225 (1978).
Jaiswal et al., Journal of Heterocyclic Chemistry, 15(3):519-521 (May 1978).
Schmiechen et al. (1990) Psychopharmacology, 102, pp. 17-20.
Strieter et al. (1988) Biochem. and Biophys. Research Comm. 155(3), pp. 1230-1236.
Taffet et al. (1989) Cell. Immunology 120, pp. 291-300.
Spengler et al. (1989) Infection and Immunity, 57(9), pp. 2837-2841.
Reeves et al. (1997) Biochem.J., 241, pp. 535-541.
Tracey et al. (1987) Nature, 330, pp. 662-664.
L.J. Old (1987) Nature, pp. 602-603.
Millar et al. The Lancet (1989) No. 8665, pp. 712-713.
DeZube et al., The Lancet (1989) No. 8690, pp. 662-663.
Molnar-Kimber (1992) Mediators of Inflammation, 1, pp. 411-417.
Schmiechen et al. (1990) Psychopharmacology, 102, pp. 17-20.
Molnar-Kimber et al. (1992) Mediators of Inflammation 1, 411-417.
Nicholson et al. (1991) Tips, vol. 12, (9 pages total).
Dent et al. (1990) Br. J. Pharm., vol. 22, p. 163.
Wyngaarden et al. (1992) XXIII Neurology, The Demyelinating Diseases, pp. 2219-2200.
Nataf et al. (1993) Acta Neurol Scand., 88: pp. 97-99.
Rott et al. (1993) Eur. J. Immunol. 23: pp. 1745-1751.
Schade et al. (1993) Eur. J. Pharm. 230: pp. 9-14.
Frohlich et al. (1988) J. Invest. Dermatolgy, 90: p. 240.
Adams et al. (1993) Principles of Neurology (5th Ed.) pp. 776-792.
Sharief et al. (1991) N.E. Jour. Med. 325(7), pp. 467-472.
Rentz et al. (1998) The J. of Immun., 141(7), pp. 2388-2393.
Benvenuto et al., J. of Neurology (1990) Supp 1 to vol. 237, pp. S83.
Kirby et al. (Aug. 30, 1980) The Lancet, pp. 453-454.
Renz et al. (1988) The Jour. of Immun., vol. 141 (7), pp. 2386-2393.
Marivet et al. (1989) J. Med. Chem., 32(7), pp. 1450-1457.
Dinter Harald
Faulds Daryl
Graf Hermann
Perez H. Daniel
Schneider Herbert
Criares Theodore J.
Schering Aktiengesellschaft
LandOfFree
Pharmaceutical preparations for TNF inhibition does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical preparations for TNF inhibition, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical preparations for TNF inhibition will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-96637